Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β2-glycoprotein i domain 1 and domain 4/5: Ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome

Arthritis and Rheumatology

Volumn 67, Issue 8, 2015, Pages 2196-2204

  Andreoli, Laura ^a   Chighizola, Cecilia B ^b   Nalli, Cecilia ^a   Gerosa, Maria ^b   Borghi, M Orietta ^b   Pregnolato, Francesca ^c   Grossi, Claudia ^c   Zanola, Alessandra ^a   Allegri, Flavio ^a   Norman, Gary L ^d   Mahler, Michael ^d   Meroni, Pier Luigi ^b   Tincani, Angela ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^d INOVA DIAGNOSTICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; BETA2 GLYCOPROTEIN 1 DOMAIN 1; BETA2 GLYCOPROTEIN 1 DOMAIN 4; BETA2 GLYCOPROTEIN 1 DOMAIN 5; IMMUNOGLOBULIN G ANTIBODY; PHOSPHOLIPID ANTIBODY; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; IMMUNOGLOBULIN G;

ADULT; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ASYMPTOMATIC DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATIC DISEASE; VEIN THROMBOSIS; CASE CONTROL STUDY; COMPLICATION; IMMUNOLOGY; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS; PROTEIN MOTIF; THROMBOSIS;

ADULT; AMINO ACID MOTIFS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS; THROMBOSIS;

EID: 84938099968     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39187     Document Type: Article

References (29)

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al., International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
2. Meroni PL, Borghi MO, Raschi E, Tedesco F., Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011; 7: 330-9.
3. Mahler M, Norman GL, Meroni PL, Khamshta M., Autoantibodies to domain 1 of β2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev 2012; 12: 313-7.
4. 2-glycoprotein I: evolution, structure and function. J Thromb Haemost 2011; 9: 1275-84.
5. Shoenfeld Y, Krause I, Kvapil F, Sulkes J, Lev S, von Landenberg P, et al., Prevalence and clinical correlations of antibodies against six β2-glycoprotein-I-related peptides in the antiphospholipid syndrome. J Clin Immunol 2003; 23: 377-83.
6. Iverson GM, Victoria EJ, Marquis DM., Anti-β2 glycoprotein I (β2GPI) autoantibodies recognize an epitope on the first domain of β2GPI. Proc Natl Acad Sci USA 1998; 95: 15542-6.
7. McNeeley PA, Dlott JS, Furie RA, Jack RM, Ortel TL, Triplett DA, et al., β2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of β2-glycoprotein I. Thromb Haemost 2001; 86: 590-5.
8. De Laat B, Pengo V, Pabinger I, Musial J, Voskuyl AE, Bultink IE, et al., The association between circulating antibodies against domain I of β2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009; 7: 1767-73.
9. 2-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum 2007; 56: 280-90.
10. 2-glycoprotein I are in close relation to patients risk categories in antiphospholipid syndrome (APS). Thromb Res 2011; 128: 583-6.
11. 2-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their 'innocent' profile? Ann Rheum Dis 2011; 70: 380-3.
12. Chighizola CB, Gerosa M, Meroni PL., New tests to detect antiphospholipid antibodies: anti-domain I β-2-glycoprotein-I antibodies. Curr Rheumatol Rep 2014; 16: 402.
13. 2-GPI. J Autoimmun 2006; 27: 266-71.
14. Arvieux J, Renaudineau Y, Mane I, Perraut R, Krilis SA, Youinou P., Distinguishing features of anti-β2 glycoprotein I antibodies between patients with leprosy and the antiphospholipid syndrome. Thromb Haemost 2002; 87: 599-605.
15. 2-glycoprotein I antibodies in children with atopic dermatitis. Int Immunol 2002; 14: 823-30.
16. Roggenbuck D, Egerer K, von Landenberg P, Hiemann R, Feist E, Burmester GR, et al., Antiphospholipid antibody profiling: time for a new technical approach? Autoimmun Rev 2012; 11: 821-6.
17. Tozzoli R, Villalta D., Autoantibody profiling of patients with antiphospholipid syndrome using an automated multiplexed immunoassay system. Autoimmun Rev 2014; 13: 59-63.
18. Pengo V, Banzato A, Bison E, Bracco A, Denas G, Ruffatti A., What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts? Semin Thromb Hemost 2012; 38: 322-7.
19. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
20. Mosca M, Neri R, Bombardieri S., Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol 1999; 17: 615-20.
21. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, et al., Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009; 7: 1737-40.
22. Tincani A, Allegri F, Balestrieri G, Reber G, Sanmarco M, Meroni P, et al., Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. Thromb Res 2004; 114: 553-8.
23. Balestrieri G, Tincani A, Spatola L, Allegri F, Prati E, Cattaneo R, et al., Anti-β 2-glycoprotein I antibodies: a marker of antiphospholipid syndrome? Lupus 1995; 4: 122-30.
24. 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005; 105: 1540-5.
25. 2-glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome. Arthritis Rheum 2013; 65: 3186-93.
26. Akhter E, Shums Z, Norman GL, Binder W, Fang H, Petri M., Utility of antiphosphatidylserine/prothrombin and IgA antiphospholipid assays in systemic lupus erythematosus. J Rheumatol 2013; 40: 282-6.
27. Agostinis C, Durigutto P, Sblattero D, Borghi MO, Grossi C, Guida F, et al., A non-complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood 2014; 123: 3478-87.
28. Borghi MO, Grossi C, Pregnolato F, Gerosa M, Andreoli L, Nalli C, et al., Anti-β2 glycoprotein I-domain I autoantibodies: comparison between two methods of detection [abstract]. 14th International Congress on Antiphospholipid Antibodies; 2013 Sep 18-21. Rio de Janeiro, Brazil.
29. 2glycoprotein I domain 1 autoantibody assays to aid in the diagnosis and risk assessment of the antiphospholipid syndrome [abstract]. Arthritis Rheum 2013; 65: S3-4.